Loading
Barcelona liver specialist who co-created the BCLC staging system used worldwide to decide how liver cancer is treated, and led STORM, which showed adjuvant sorafenib does not help after curative treatment.
Jordi Bruix led the Barcelona Clinic Liver Cancer (BCLC) group at Hospital Clínic de Barcelona, whose staging and treatment algorithm is the reference framework for hepatocellular carcinoma. He was first author of the 2015 Lancet Oncology report of STORM, which found that sorafenib after resection or ablation did not improve recurrence-free survival, and a senior investigator on the SHARP trial that established sorafenib for advanced disease.
| Title | Journal | Year |
|---|---|---|
| STORM: adjuvant sorafenib after resection or ablation of hepatocellular carcinoma | The Lancet Oncology | 2015 |
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tags hcc, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Hospital Clínic de Barcelona / IDIBAPS, Hepatocellular carcinoma and the tags hcc, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Hepatocellular carcinoma.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Advanced hepatocellular carcinoma (BCLC C).